Efficacy of troglitazone measured by insulin resistance index.
作者信息
Nagasaka S, Iwamoto Y, Ishikawa S, Kuzuya T, Saito T
出版信息
Lancet. 1997 Jul 19;350(9072):184. doi: 10.1016/s0140-6736(05)62350-1.
PMID:9250189
Abstract
摘要
相似文献
1
Efficacy of troglitazone measured by insulin resistance index.通过胰岛素抵抗指数测定的曲格列酮疗效。
Lancet. 1997 Jul 19;350(9072):184. doi: 10.1016/s0140-6736(05)62350-1.
2
Learning to use troglitazone.学习使用曲格列酮。
Diabetes Care. 1998 Sep;21(9):1389-90. doi: 10.2337/diacare.21.9.1389.
3
New diabetes drug targets insulin resistance.
Am J Health Syst Pharm. 1997 Mar 15;54(6):623, 625. doi: 10.1093/ajhp/54.6.623.
4
Troglitazone: a new antihyperglycemic agent.曲格列酮：一种新型抗高血糖药物。
Cleve Clin J Med. 1997 May;64(5):238-40. doi: 10.3949/ccjm.64.5.238.
5
Troglitazone and small low-density lipoprotein in type 2 diabetes.
Ann Intern Med. 1998 Jul 15;129(2):162-3. doi: 10.7326/0003-4819-129-2-199807150-00030.
6
New directions in treating insulin resistance.治疗胰岛素抵抗的新方向。
Hosp Pract (1995). 1995 Sep 15;30(9):9-10. doi: 10.1080/21548331.1995.11443246.
7
Effect of troglitazone on lipoprotein(a) levels in obese subjects.
Diabetes Care. 1999 Oct;22(10):1752-3. doi: 10.2337/diacare.22.10.1752.
8
9
[A 75-year-old type 2 diabetes mellitus case responding strikingly troglitazone: possible mechanism of insulin resistance induced by insulin antibody].[一例75岁2型糖尿病患者对曲格列酮反应显著：胰岛素抗体诱导胰岛素抵抗的可能机制]
Nihon Ronen Igakkai Zasshi. 2000 Apr;37(4):344-8. doi: 10.3143/geriatrics.37.344.
10
New therapeutic approaches to reversing insulin resistance.逆转胰岛素抵抗的新治疗方法。
Curr Opin Nephrol Hypertens. 1998 Sep;7(5):551-5. doi: 10.1097/00041552-199809000-00011.
引用本文的文献
1
Misuse of correlation and regression in three medical journals.三本医学期刊中相关性和回归分析的误用
J R Soc Med. 1999 Mar;92(3):123-8. doi: 10.1177/014107689909200306.
2
Abnormalities of vascular endothelial function may contribute to increased coronary heart disease risk in UK Indian Asians.血管内皮功能异常可能会增加英国印度裔亚洲人患冠心病的风险。
Heart. 1999 May;81(5):501-4. doi: 10.1136/hrt.81.5.501.
Zotero 插件